VRDN
Viridian Therapeutics, Inc.\de Health Care Pharmaceutical Preparations Russell 3000
$24.67Close
$2.5BMarket cap
$13.30 – $33.7852-week range
Nov 4, 2026Next report · before the open
Highlights
Strengths
- Leading the market RS 81 · stronger than 81% of stocks over 12 months
Cautions
- Not in an uptrend 4 of 8 trend conditions
- Far from its high 27% below its 52-week high
- Results soon Nov 4, 2026, in 3 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
27%
1wk
up 10.3%
price change
1mo
up 19.8%
price change
12-month return
up 4%
market up 11% ·
its own down 4%
F-score
—
— Not assessed
Altman Z
6.26
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
3.5×
price / book
Earnings yield
down 15.8%
EBIT / enterprise value
Cheaper than
20%
of the market · expensive
Revenue growth
up 23360%
year on year
EPS growth
—
latest quarter
Sales growth
up 279%
latest quarter · +183 pts
ROE
down 49%
return on equity
Free cash margin
down 391%
-$276.9M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- Revenue reaccelerating (-4% then +23360%)
Trade setup
ATR%
3.9%
$0.97 a day · 2×ATR $22.72
RS
81 / 99
vs the universe
Trend
4 / 8
trend template
Relative volume
1.0×
vs 50-day average
Up/down volume
1.07
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 4 of 8
- Price above the 150 and 200-day averages: passes
- 150-day average above the 200-day: fails
- 200-day average rising for a month: fails
- 50-day average above the 150 and 200-day: fails
- Price above the 50-day average: passes
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 25.7% over the year, from 81m to 102m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026+12% vs market2 sessions after results
Financials
- Net -484%
- Free cash -391%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1M | $3.0M | $1.8M | $314,000 | $302,000 | $70.8M |
| Operating income | -$110.4M | -$79.7M | -$134.3M | -$254.4M | -$299.0M | -$363.4M |
| Net income | -$110.7M | -$79.4M | -$129.9M | -$237.7M | -$269.9M | -$342.6M |
| Net margin | -10544% | -2680% | -7331% | -75701% | -89371% | -484% |
| Earnings per share | -$31.13 | -$6.66 | -$4.05 | -$5.31 | — | — |
| Free cash flow | -$29.8M | -$54.9M | -$94.6M | -$185.1M | -$232.8M | -$276.9M |
| Free cash margin | -2840% | -1853% | -5341% | -58939% | -77096% | -391% |
| Cash | $45.9M | $42.3M | $155.6M | $102.8M | $99.6M | $212.4M |
| Long-term debt | $0 | $0 | $4.6M | $20.2M | $20.6M | — |
| Shareholders' equity | $120.0M | $187.7M | $395.1M | $442.0M | $671.6M | $722.2M |
| Shares outstanding | 4.23m | 23.92m | 41.31m | 53.99m | 80.99m | 101.83m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 5, 2026 | Quarterly ↗ | Mar 31, 2026 | 35d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 6, 2025 | Quarterly ↗ | Mar 31, 2025 | 36d |
| Mar 3, 2025 | Annual ↗ | Dec 31, 2024 | 62d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Feb 27, 2024 | Annual ↗ | Dec 31, 2023 | 58d |
| Nov 13, 2023 | Quarterly ↗ | Sep 30, 2023 | 44d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 6, 2026 | Results ↗ |
| Jun 29, 2026 | Regulation FD · Other events ↗ |
| Jun 3, 2026 | Shareholder vote ↗ |
| May 28, 2026 | Agreement ended ↗ |
| May 26, 2026 | Material agreement ↗ |
| May 11, 2026 | Material agreement · New obligation · Other events ↗ |
| May 5, 2026 | Regulation FD ↗ |
| May 5, 2026 | Results ↗ |
| Mar 30, 2026 | Regulation FD ↗ |
| Feb 26, 2026 | Results ↗ |
| Nov 5, 2025 | Results ↗ |
| Oct 23, 2025 | Material agreement ↗ |